Supplementary DataTable 1: Post-hoc classification of chemotherapy FN risk according to the textbook regimen.
Tumour type / Chemotherapy regimen / FN Risk (%) / ReferenceBreast
CMF (Bonadonna) / <10 / 1
CMF (modified) / <10 / 1
AC / <10 / 1
EC / <10 / 3
FAC / <10 / 1
FEC100 / 10-20 / 1
FEC90 / 10-20 / 4
AC-Doc / >20 / 1
AC-Pac / <10 / 1
dd AC-Pac / >20 / 2
EC-Doc / >20 / 5
EC-Pac / <10 / 6
FEC-Doc / >20 / 7
FEC-Pac / <10 / 8
dd E-T-CMF / >20 / 9
ADoc / >20 / 1
APac / >20 / 1
DocC / 10-20 / 10
CarboPac / <10 / 11
DocAC ("TAC") / >20 / 1
DocEC / >20 / 12
EDoc / >20 / 13
EPac / 10-20 / 14
Paclitaxel / <10 / 15
Doc100 / 10-20 / 1
XDoc / 10-20 / 1
PLD / <10 / 16
CycloPLD (q4w) / <10 / 17
CycloPLD (q3w) / <10 / 18
DocPLD / 10-20 / 19
Vin (oral) / <10 / 20
Vin (d1,8,15) / <10 / 21
GemDoc / <10 / 22
GemPac / <10 / 23
A-Pac / <10 / author opinion
Ovarian
CarboDoc / 10-20 / 24
CarboGem / <10 / 25
CarboPac / <10 / 3
CisDoc / 10-20 / author opinion
CisEtoBleo (PEB, Cis low-dose) / 10-20 / 26
CisEtoBleo (PEB) / 10-20 / 27
CisGem (Cis low-dose) / <10 / 1
CisPac / <10 / 28
Gemcitabine / <10 / 29
Paclitaxel / <10 / 30
PLD / <10 / 31
Topotecan / 10-20 / 1
CarboMono / <10 / author opinion
CarboPLD / <10 / 32
SCLC
CarboDoc / 10-20 / author opinion
CarboEto (Eto 100) / 10-20 / 1
CarboPac / <10 / 1
CarboVin / 10-20 / 33
CisEto (q4w) / 10-20 / 34
CDE (AC-Eto) / >20 / 1
CAV / 10-20 / 1
Doc100 / 10-20 / 35
Doc75 / 10-20 / 36
Topotecan / >20 / 1
NSCLC
CarboDoc / 10-20 / 37
CarboEto (Eto 200) / >20 / 38
CarboGem / <10 / 39
CarboPac / <10 / 1
CarboVin / 10-20 / 40
CisDoc (6x q3w) / 10-20 / 1
CisEto (Cis low/Eto high) / >20 / 1
CisEto (q3w) / 10-20 / 2
CisGem (q4w) / <10 / 41
CisGem (q3w) / <10 / 42
CisPem / <10 / 42
CisVin (q4w) / 10-20 / 43
CisVin (adj) / 10-20 / 2
CisVin (q3w) / 10-20 / 44
Doc100 / 10-20 / 45
Doc75 / 10-20 / 46
Gemcitabine / <10 / 47
Vin (d1,8) / <10 / 48
CisPac / 10-20 / 49
MIC / <10 / 50
Pem / <10 / 51
A, doxorubicin; Carbo, carboplatin;Cis, cisplatin; C, cyclophosphamide; dd, dose-dense; Doc, docetaxel; E, epirubicin; Eto,etoposide; F, fluorouracil; Gem, gemcitabine; M, methotrexate; MIC, mitomycin, ifosfamide, cisplatin;
Pac, paclitaxel; Pem, pemetrexed; PLD, pegylated liposomal doxorubicin; T, paclitaxel; V, vincristine; Vin, vinorelbine; X, capecitabine.
References:
1. Aapro MS, Bohlius J, Cameron DA, et al. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32.
2. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M; National Comprehensive Cancer Network. Myeloid growth factors. J Natl Compr Canc Netw 2011, 9, 914-932.
3. Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, SommerH, Morack G, Wischnewsky MB, Lichtenegger W, Kuemmel S. Epirubicin andcyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. AnnOncol. 2010 Jul;21(7):1430-5.
4. Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V,Brodowicz T. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil,epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter,prospective, randomized phase III trial. J Clin Oncol. 2005 Mar 1;23(7):1401-8.
5. Eckhoff L, Nielsen M, Moeller S, Knoop A. TAXTOX - a retrospective studyregarding the side effects of docetaxel given as part of the adjuvant treatmentto patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol. 2011 Oct;50(7):1075-82.
6. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W,Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionallyscheduled chemotherapy in high-risk primary breast cancer: mature results of anAGO phase III study. J Clin Oncol. 2010 Jun 10;28(17):2874-80.
7. Fraser J, Steele N, Al Zaman A, Yule A. Are patients in clinical trialsrepresentative of the general population? Dose intensity and toxicitiesassociated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. Eur J Cancer. 2011Jan;47(2):215-20.
8. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M,Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, GuitiánMD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia MarcoJM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A,Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun4;100(11):805-14.
9. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E,Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E,Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I,Karanikiotis C, Dimopoulos AM; Hellenic Cooperative Oncology Group. Postoperativedose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF inpatients with high-risk breast cancer: safety analysis of the HellenicCooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008May;19(5):853-60.
10. Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB. Febrileneutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylacticpegfilgrastim in breast cancer patients: a retrospective analysis. Med Oncol.2012 Sep;29(3):1495-501.
11. Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A,Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaides C, Keramopoulos A,Pavlidis N, Kosmidis P, Skarlos D. First-line chemotherapy with paclitaxel bythree-hour infusion and carboplatin in advanced breast cancer (final report): aphase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol.1998 Sep;9(9):1031-4.
12. Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E,Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M. Dose-dense adjuvantchemotherapy in node-positive breast cancer: docetaxel followed byepirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks.AERO B03 randomized phase II study. Ann Oncol. 2007 Jan;18(1):52-7.
13. Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N,Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N,Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology ResearchGroup. Randomized phase III trial comparing docetaxel plus epirubicin versusdocetaxel plus capecitabine as first-line treatment in women with advanced breastcancer. Ann Oncol. 2010 Jan;21(1):48-54.
14. Lück HJ, Thomssen C, du Bois A, Untch M, Lisboa B, Köhler G, Diergarten K.Phase II study of paclitaxel and epirubicin as first-line therapy in patientswith metastatic breast cancer. Semin Oncol. 1997 Oct;24(5 Suppl17):S17-35-S17-39.
15. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomizedcomparative study of two doses of paclitaxel in patients with metastatic breastcancer. J Clin Oncol. 1996 Jun;14(6):1858-67.
16. Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G, Oberaigner W, Hausmaninger H. Phase II study of single-agent pegylated liposomal doxorubicinHCl (PLD) in metastatic breast cancer after first-line treatment failure.Onkologie. 2004 Oct;27(5):441-6.
17. Martín M, Sánchez-Rovira P, Muñoz M, Baena-Cañada JM, Mel JR, Margeli M, RamosM, Martínez E, García-Saenz JA, Casado A, Jaén AM, González-Farré X, Escudero MJ,Rodriguez-Martin C, Carrasco E; GEICAM. Pegylated liposomal doxorubicin incombination with cyclophosphamide and trastuzumab in HER2-positive metastaticbreast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05study. Ann Oncol. 2011 Dec;22(12):2591-6.
18. Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF. Phase II multicentertrial of anthracycline rechallenge with pegylated liposomal doxorubicin pluscyclophosphamide for first-line therapy of metastatic breast cancer previouslytreated with adjuvant anthracyclines. J Clin Oncol. 2009 Dec 10;27(35):5906-10.
19. Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA,Davidson NE. Phase II trial of pegylated liposomal doxorubicin plus docetaxelwith and without trastuzumab in metastatic breast cancer: Eastern CooperativeOncology Group trial E3198. Breast Cancer Res Treat. 2010 May;121(1):111-20.
20. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K,Trillet-Lenoir V. Phase II study of oral vinorelbine in first-line advancedbreast cancer chemotherapy. J Clin Oncol. 2003 Jan 1;21(1):35-40.
21. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R,Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S,Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer StudyInvestigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20.
22. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Antón A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P. Phase III study ofgemcitabine plus docetaxel compared with capecitabine plus docetaxel foranthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol.2009 Apr 10;27(11):1753-60.
23. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A,Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J.Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients withmetastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008Aug 20;26(24):3950-7.
24. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase IIIrandomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin asfirst-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov17;96(22):1682-91.
25. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U,Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J,Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG;EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of theAGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct10;24(29):4699-707.
26. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy ofovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of theGynecologic Oncology Group. J Clin Oncol. 1994 Apr;12(4):701-6.
27. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, SilvaEG, Wharton JT. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990 Apr;8(4):715-20.
28. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W,Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer StudyGroup. A randomized clinical trial of cisplatin/paclitaxel versuscarboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl CancerInst. 2003 Sep 3;95(17):1320-9.
29. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, DelMedico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial ofgemcitabine compared with pegylated liposomal doxorubicin in progressive orrecurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6.
30. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S,Spiegel G, Arbuck SG. Phase III trial of paclitaxel at two dose levels, thehigher dose accompanied by filgrastim at two dose levels in platinum-pretreatedepithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003 Aug1;21(15):2843-8.
31. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrentepithelial ovarian carcinoma: a randomized phase III study of pegylated liposomaldoxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22.
32. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, VaseyPA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A,Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylatedliposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatinfor patients with platinum-sensitive ovarian cancer in late relapse. J ClinOncol. 2010 Jul 10;28(20):3323-9.
33. Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C,D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, DePlacido S, Gallo C, Monfardini S, Bianco AR. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-celllung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol. 1998 Apr;16(4):1414-9.
34. Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL,Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin pluscyclophosphamide in treatment of extensive small-cell lung cancer: a FrenchFederation of Cancer Institutes multicenter phase III randomized study. J NatlCancer Inst. 2001 Feb 21;93(4):300-8.
35. Hesketh PJ, Crowley JJ, Burris HA 3rd, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livingston RB, Gandara DR. Evaluation ofdocetaxel in previously untreated extensive-stage small cell lung cancer: aSouthwest Oncology Group phase II trial. Cancer J Sci Am. 1999Jul-Aug;5(4):237-41.
36. Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer EA. Phase IIstudy of docetaxel (taxotere) in patients with previously untreated extensivesmall cell lung cancer. Invest New Drugs. 1996;13(4):343-5.
37. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E,Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized,multinational, phase III study of docetaxel plus platinum combinations versusvinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24.
38. Jeremic B, Shibamoto Y, Milicic B, Milisavljevic S, Nikolic N, Dagovic A,Aleksandrovic J, Radosavljevic-Asic G. Prolonged oral versus high-doseintravenous etoposide in combination with carboplatin for stage IV non-small-celllung cancer (NSCLC): a randomized trial. Lung Cancer. 1999 Sep;25(3):207-14.
39. Masters GA, Li S, Dowlati A, Madajewicz S, Langer C, Schiller J, Johnson D. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) inpatients with advanced non-small cell lung cancer: an Eastern CooperativeOncology Group study (E1501). J Thorac Oncol. 2006 Sep;1(7):673-8.
40. Agelaki S, Bania H, Kouroussis C, Blazoyiannakis G, Souglakos J, Tsiafaki X,Kalbakis K, Rapti A, Androulakis N, Georgoulias V, Papadakis E. Second-linetreatment with vinorelbine and carboplatin in patients with advanced non-smallcell lung cancer. A multicenter phase II study. Lung Cancer. 2001 Dec;34 Suppl4:S77-80.
41. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U,Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH.Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol.2000 Jan;18(1):122-30.
42. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C,Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K,Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. PhaseIII study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. JClin Oncol. 2008 Jul 20;26(21):3543-51.
43. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E,Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized,multinational, phase III study of docetaxel plus platinum combinations versusvinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24.
44. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecanversus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatinplus vinorelbine for advanced non-small-cell lung cancer: Four-Arm CooperativeStudy in Japan. Ann Oncol. 2007 Feb;18(2):317-23.
45. Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E,Toumbis M, Kouroussis C, Syrigos K, Polyzos A, Samaras N, Papakotoulas P,Christofilakis C, Ziras N, Alegakis A. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: arandomized, multicenter phase III trial. J Clin Oncol. 2004 Jul 1;22(13):2602-9.
46. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N,Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospectiverandomized trial of docetaxel versus best supportive care in patients withnon-small-cell lung cancer previously treated with platinum-based chemotherapy. JClin Oncol. 2000 May;18(10):2095-103.
47. Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, MaiorinoL, Guida M, Panza N, Mancarella S, Cioffi R. Gemcitabine with either paclitaxelor vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advancednon-small-cell lung cancer patients. Br J Cancer. 2004 Aug 2;91(3):489-97.
48. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, SawaT, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M.Phase III study of docetaxel compared with vinorelbine in elderly patients withadvanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006 Aug 1;24(22):3657-63.
49. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J,Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapyregimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan10;346(2):92-8.
50. Sculier JP, Lafitte JJ, Berghmans T, Van Houtte P, Lecomte J, Thiriaux J,Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P,Paesmans M, Mommen P, Ninane V; European Lung Cancer Working Party. A phase IIIrandomised study comparing two different dose-intensity regimens as inductionchemotherapy followed by thoracic irradiation in patients with advancedlocoregional non-small-cell lung cancer. Ann Oncol. 2004 Mar;15(3):399-409.
51. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J,Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R,Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomizedphase III trial of pemetrexed versus docetaxel in patients with non-small-celllung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May1;22(9):1589-97.
1